The NCCN has updated its colorectal cancer (CRC) guidelines, recommending a weekly regorafenib dose-escalation strategy beginning at 80 mg and ending at 160 mg for previously treated patients with metastatic CRC.
Original Article: NCCN Recommends Regorafenib Dose Escalation in Metastatic CRC
NEXT ARTICLE